Theragenics (FRA:THX) Interest Expense : €-0.45 Mil (TTM As of Jun. 2013)

View and export this data going back to . Start your Free Trial

What is Theragenics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Theragenics's interest expense for the three months ended in Jun. 2013 was € -0.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2013 was €-0.45 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Theragenics's Operating Income for the three months ended in Jun. 2013 was € 0.10 Mil. Theragenics's Interest Expense for the three months ended in Jun. 2013 was € -0.10 Mil. Theragenics's Interest Coverage for the quarter that ended in Jun. 2013 was 0.95. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theragenics Interest Expense Historical Data

The historical data trend for Theragenics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theragenics Interest Expense Chart

Theragenics Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Interest Expense

Get a 7-Day Free Trial

-0.62

-0.59

-0.74

-0.53

-0.48

Theragenics Quarterly Data
	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13
Interest Expense	Get a 7-Day Free Trial															-0.12	-0.13	-0.11	-0.11	-0.10

Theragenics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.45 Mil.

Theragenics (FRA:THX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theragenics's Interest Expense for the three months ended in Jun. 2013 was €-0.10 Mil. Its Operating Income for the three months ended in Jun. 2013 was €0.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2013 was €16.68 Mil.

Theragenics's Interest Coverage for the quarter that ended in Jun. 2013 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2013 )	/	Interest Expense (Q: Jun. 2013 )
	=	-1	*	0.099	/	-0.104
	=	0.95

The higher the ratio, the stronger the company's financial strength is.

Theragenics (FRA:THX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theragenics Corporation (FRA:THX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.theragenics.com

Theragenics Corporation is a Delaware Corporation formed in 1981. It is a medical device company serving the surgical products and cancer treatment markets, operate in two business segments; the surgical products segment and the brachytherapy seed segment. The Company's surgical products business manufactures markets and sells disposable devices utilized in certain surgical procedures. Its brachytherapy seed business manufactures markets and sells radioactive 'seeds' utilized in the treatment of early stage prostate cancer. Its surgical products business was built through the acquisitions of CP Medical Corp. in May 2005, Galt Medical Corporation in August 2006, and NeedleTech Products, Inc. in July 2008. The Company manufactures almost 3,500 products in this business as part of three broad product platforms; wound closure, vascular access and specialty needles. It serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. With the exception of veterinary sutures, its surgical products hold relatively small market shares. Its products include both finished goods and components. The Company's products are sold mainly to original equipment manufacturers and to a network of distributors. The Company's facilities and operations are subject to extensive environmental, nuclear, regulatory and occupational health and safety laws at the federal, state and local levels. It is also subject to similar foreign laws and regulations under certain circumstances when its products are distributed outside of the United States.

Theragenics (FRA:THX) Headlines

No Headlines